While Novavax, Inc has overperformed by 1.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVAX fell by -55.67%, with highs and lows ranging from $17.81 to $5.01, whereas the simple moving average fell by -19.77% in the last 200 days.
On February 28, 2025, BTIG Research started tracking Novavax, Inc (NASDAQ: NVAX) recommending Buy. A report published by JP Morgan on July 30, 2024, Downgraded its rating to ‘Underweight’ for NVAX. BofA Securities May 10, 2024d the rating to Neutral on May 10, 2024, and set its price target from $4 to $12. B. Riley Securities August 09, 2023d its ‘Neutral’ rating to ‘Buy’ for NVAX, as published in its report on August 09, 2023. TD Cowen’s report from April 20, 2023 suggests a price prediction of $10 for NVAX shares, giving the stock a ‘Market Perform’ rating. B. Riley Securities also rated the stock as ‘Neutral’.
Analysis of Novavax, Inc (NVAX)
Further, the quarter-over-quarter increase in sales is 610.30%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Novavax, Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. Taking into account the quick ratio of the company, currently set at 2.03, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and NVAX is recording an average volume of 8.54M. On a monthly basis, the volatility of the stock is set at 4.68%, whereas on a weekly basis, it is put at 2.02%, with a loss of -5.13% over the past seven days. Furthermore, long-term investors anticipate a median target price of $14.67, showing growth from the present price of $7.03, which can serve as yet another indication of whether NVAX is worth investing in or should be passed over.
How Do You Analyze Novavax, Inc Shares?
A leading company in the Biotechnology sector, Novavax, Inc (NVAX) is based in the USA. When comparing Novavax, Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 2.65, there is a growth in quarterly earnings of 376.87%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.87%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 56.77% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NVAX shares are owned by institutional investors to the tune of 56.77% at present.
